Profusa Achieves Milestones, Commits to Groundbreaking Biochemistry Tech.

Profusa, a digital health company, has achieved significant milestones, including going public on the Nasdaq Market. The company's Chairman and CEO, Ben Hwang, Ph.D., provided a strategy overview and business update. Profusa's technology platform enables continuous monitoring of an individual's biochemistry, and the company is committed to bringing this groundbreaking technology to the clinical community to drive growth in its business.

Profusa, Inc. (NASDAQ: PFSA), a commercial stage digital health company, has achieved significant milestones following its Nasdaq listing on July 14, 2025. The company's Chairman and CEO, Ben Hwang, Ph.D., provided a comprehensive strategy overview and business update in a recent letter to shareholders. Profusa's technology platform enables continuous monitoring of an individual's biochemistry and is poised to drive growth in the digital health sector.

Key developments include securing a $100 million ELOC facility for growth funding and planning the European launch of its Lumee™ platform for tissue oxygen monitoring in Q1 2026. The company aims for a U.S. FDA submission mid-2026, with commercialization expected in 2027. Additionally, Profusa's glucose monitoring platform, targeting a 500 million patient market, is progressing with human validation data expected from EU and APAC clinical sites, targeting commercialization by mid-2027.

Profusa has established five strategic pillars to guide its growth: revenue growth and pipeline development, AI infrastructure development, clinical and regulatory pathways, financial structure and strategies, and scale of operations. These pillars are designed to maximize shareholder value and drive forward the company's technological and financial achievements.

The company's revenue growth side is on track to generate revenue from research use only applications of its technology platform, which will be immediately additive to its commercial operations. Profusa is also progressing towards the European launch of its Lumee™ platform, with an estimated $10 billion global addressable market for tissue oxygen biochemistry monitoring.

Profusa's continuous glucose monitoring platform targets a global addressable market of more than 500 million patients, with human validation data from EU and APAC clinical sites expected to be published in a peer-reviewed journal. The company aims to commence human pivotal studies later in 2026, with the goal of commercialization by mid-2027.

To secure its financial stability, Profusa has secured a $100 million ELOC facility, which it believes will provide ample funding for its phase of growth. The company is implementing a strategic treasury plan utilizing digital investment to manage its resources and align with a digital future.

Profusa remains dedicated to bringing its game-changing technology to the clinical community, recognizing the potential this monitoring platform offers to a wide array of patients and users, including those with debilitating and/or chronic diseases. The company is confident that its five pillars will provide the organization necessary to drive forward in a focused manner.

For more information, visit [Profusa's website](https://profusa.com).

References:
[1] https://www.stocktitan.net/news/PFSA/profusa-inc-provides-strategy-overview-and-business-update-for-vnywgan2tsbl.html